Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines

Inclusion Criteria: Original study: * Written informed consent obtained from the parent/legal guardian of the subject. * Free of obvious health problems as established by medical history and/or clinical examination before entering the study. * At least 8 kg of body weight at age of 12 months. Follow-up phase: * Subjects enrolled and randomised in the original study and having received two doses of the hepatitis A study vaccines. Exclusion Criteria: Original study: * Children not having received 3 documented doses of DTPaHib and polio vaccines during infancy * Children having received a documented dose of MMR during infancy * Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and the 30 days safety follow-up after the last dose. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Administration of systemic corticosteroids (inhaled and topical steroids are allowed). * Administration of a vaccine not foreseen by the study protocol within 4 weeks prior to the first dose of study vaccine. * Previous vaccination against hepatitis A. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Major congenital defects or serious chronic illness * Acute disease at the time of enrolment. Follow-up phase: * Children who had received a hepatitis A antigen containing vaccine since the last visit